相关实验视频

Updated: Jul 12, 2025

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

戈利穆马布和乌斯特基努马布对流通的树突细胞迁移能力在炎症性肠道疾病的影响

Irene Soleto¹, Cristina Ramirez¹, Cristina Gómez¹

¹Gastroenterology Unit, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), 28006 Madrid, Spain.

|October 28, 2023

概括

2型常规树突细胞 (cDC2) 在炎症性肠病 (IBD) 中,向肠道迁移的增加. 诸如戈利穆马布和乌斯特基努马布之类的治疗改变了树突细胞 (DC) 迁移模式,为IBD提供了潜在的治疗点.

科学领域:

免疫学免疫学免疫学
胃肠病学胃肠病学
细胞生物学细胞生物学

背景情况:

炎症性肠病 (IBD),包括性结肠炎 (UC) 和克罗恩病 (CD),涉及由于过度活跃的免疫反应导致的慢性肠道炎症.
树突细胞 (DCs) 是粘膜免疫中的关键抗原呈现细胞,它们在IBD中的增加招募表明它们在疾病发病过程中的作用.
在IBD中,驱动DC向炎症肠道迁移的精确机制尚不完全理解.

研究的目的:

研究IBD患者循环直流子集的指向标和迁移潜力的表达.
评估golimumab和ustekinumab对DC迁移对肠道化疗信号的反应的影响.
为了比较IBD患者和健康对照者之间的DC迁移特征.

主要方法:

分析循环树突细胞 (DC) 子集上的指向标表达.
对各种肠道化学基因 (例如,CCL2,CCL25,MadCam1) 的DC迁移能力的评估.
对IBD (UC和CD) 患者和健康对照患者的DC迁移概况进行比较,包括评估golimumab和ustekinumab治疗效果.

主要成果:

与其他DC子集相比,2型常规树突细胞 (cDC2) 的迁移概况显著更高.
在UC和CD患者中,戈利马布和乌斯特基马布对cDC1迁移表现出不同的影响.
虽然CCL2没有化学吸引DC,但golimumab和ustekinumab增强了DC向CCL2和CCL25的迁移,同时减少了向MadCam1.1的迁移.

结论:

cDC2细胞对胃肠道粘膜有较高的迁移倾向,这表明它们在IBD病变发生过程中起着关键作用.
这些发现表明,戈利穆马布和乌斯特基努马布可以调节IBD患者的DC迁移模式.
这些结果为开发新的诊断生物标志物和IBD的免疫调节治疗策略提供了潜在的途径.

关键词:

克罗恩氏病是什么克罗恩氏病是什么树突细胞的树突细胞.这就是golimumab.炎症性肠病是一种炎症性肠病.性结肠炎是一种乌斯蒂基诺姆巴布 (乌斯蒂基诺姆巴布) 是

更多相关视频

Isolation and Characterization of Dendritic Cells and Macrophages from the Mouse Intestine

Isolation and Characterization of Dendritic Cells and Macrophages from the Mouse Intestine

Published on: May 21, 2012

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells

Published on: May 18, 2018

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Inflammatory Bowel Disease II: Crohn's Disease

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Inflammatory Bowel Disease I: Ulcerative Colitis

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...